Frontiers in Oncology最新文献

{"title":"Prognostic value of disulfidptosis-associated genes in gastric cancer: a comprehensive analysis.","authors":"Jin Tang, Jing Yang, Long-Kuan Yin","doi":"10.3389/fonc.2025.1512394","DOIUrl":"10.3389/fonc.2025.1512394","url":null,"abstract":"<p><strong>Objective: </strong>Disulfidptosis is a newly identified type of nonapoptotic programmed cell death related to mechanisms such as ferroptosis, cuproptosis, pyroptosis, and necrotic apoptosis. This study explores the role of disulfidptosis-related long non-coding RNAs (DRLs) in gastric cancer and their potential as prognostic biomarkers.</p><p><strong>Method: </strong>We developed a prognostic model using DRL scores to classify patients based on disulfidptosis activity. We evaluated these scores for correlations with drug sensitivity, tumor microenvironment (TME) features, tumor mutational burden (TMB), and prognosis. Potential disulfidptosis-related signaling pathways were screened, identifying FRMD6-AS as a promising therapeutic target. FRMD6-AS expression was further validated using real-time fluorescent quantitative PCR (qRT-PCR).</p><p><strong>Results: </strong>The DRL-based prognostic model, established through univariate and multivariate Cox regression and LASSO regression analyses, outperformed traditional models in predicting prognosis. We divided samples into high-risk and low-risk groups based on DRL scores, finding that the low-risk group had a significantly higher survival rate (P < 0.05). A high-precision prediction model incorporating DRL scores, age, sex, grade, and stage showed strong predictive value and consistency with actual outcomes. High DRL scores correlated with higher TME scores and lower TMB. Key signaling axes identified were AC129507.1/(FLNA, TLN1)/FOCAL ADHESION and AC107021.2/MYH10/(TIGHT JUNCTION, VIRAL MYOCARDITIS, REGULATION OF ACTIN CYTOSKELETON). Potentially effective drugs, including BMS-754807, dabrafenib, and JQ1, were identified. FRMD6-AS emerged as a potential target for gastric cancer treatment.</p><p><strong>Conclusions: </strong>This study developed a novel prognostic model for gastric cancer using DRLs, identifying two key signaling axes related to prognosis. JQ1 may be an effective treatment, and FRMD6-AS could be a promising therapeutic target.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1512394"},"PeriodicalIF":3.5,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11913695/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case of high-grade adenosquamous carcinoma of the breast: case report and literature review.","authors":"Xiaoxiao Xing, Junyi Li, Yangyang Fan, Yun Wang, Yue Wang, Daixiang Liao, Shiyun Zhang","doi":"10.3389/fonc.2025.1548036","DOIUrl":"10.3389/fonc.2025.1548036","url":null,"abstract":"<p><p>High-grade adenosquamous carcinoma (HGASC) is a rare and aggressive subtype of metaplastic breast cancer (MpBC). This article reports a case of HGASC (pT2N0M0 Stage IIA) in a 43-year-old female and reviews the relevant literature, with a specific focus on distinguishing HGASC from other MpBC subtypes, particularly low-grade adenosquamous carcinoma (LGASC). The patient underwent a skin-sparing mastectomy with abdominal rectus myocutaneous flap reconstruction. Histopathology confirmed HGASC with metaplastic features. Postoperative adjuvant chemotherapy with capecitabine was administered. The case highlights the unique clinical, imaging, and pathological characteristics of HGASC, its therapeutic challenges, and the need for individualized treatment strategies. A five-month follow-up showed no signs of recurrence or metastasis.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1548036"},"PeriodicalIF":3.5,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11915217/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multi-omics approach reveals the impact of prognosis model-related genes on the tumor microenvironment in medulloblastoma.","authors":"Dongming Han, Xuan Chen, Xin Jin, Jiankang Li, Dongyang Wang, Ziwei Wang","doi":"10.3389/fonc.2025.1477617","DOIUrl":"10.3389/fonc.2025.1477617","url":null,"abstract":"<p><strong>Background: </strong>The tumor microenvironment (TME) significantly impacts the progression and prognosis of medulloblastoma (MB). This study aimed to develop a TME-associated risk score(TMErisk) model using RNA sequencing data to predict patient outcomes and elucidate biological mechanisms.</p><p><strong>Methods: </strong>RNA sequencing data from 322 Tiantan and 763 GSE85217 MB samples were analyzed. Key gene modules related to immune and stromal components were identified using Weighted Gene Co-expression Network Analysis (WGCNA). Significant genes were screened using LASSO-COX and COX regression models. Single-cell RNA sequencing (scRNA-seq), single-cell ATAC sequencing (scATAC-seq), and spatial RNA analyses validated the findings.</p><p><strong>Results: </strong>Differential expression analysis identified 731 upregulated and 15 downregulated genes in high vs. low immune score MB patients, and 686 upregulated and 43 downregulated genes in high vs. low stromal score patients. Eight key genes (<i>CEBPB</i>, <i>OLFML2B</i>, <i>GGTA1</i>, <i>GZMA</i>, <i>TCIM</i>, <i>OLFML3</i>, <i>NAT1</i>, and <i>CD1C</i>) were included in the TMErisk model, which demonstrated strong prognostic power. High TMErisk scores correlated with poorer survival, distinct immune cell infiltration patterns, and lower tumor cell stemness. Single-cell analyses revealed the expression dynamics of TMErisk genes across cell types, including macrophages, T cells, and NK cells, and identified key regulatory transcription factors. Spatial transcriptomics showed significant clustering of TMErisk genes in tumor regions, highlighting spatial heterogeneity and the formation of immune hubs.</p><p><strong>Conclusions: </strong>The TMErisk model enhances our understanding of the MB tumor microenvironment, serving as a robust prognostic tool and suggesting new avenues for targeted therapy.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1477617"},"PeriodicalIF":3.5,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11913712/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EUS-based intratumoral and peritumoral machine learning radiomics analysis for distinguishing pancreatic neuroendocrine tumors from pancreatic cancer.","authors":"Shuangyang Mo, Nan Yi, Fengyan Qin, Huaying Zhao, Yingwei Wang, Haiyan Qin, Haixiao Wei, Haixing Jiang, Shanyu Qin","doi":"10.3389/fonc.2025.1442209","DOIUrl":"10.3389/fonc.2025.1442209","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to develop and validate intratumoral, peritumoral, and combined radiomic models based on endoscopic ultrasonography (EUS) for retrospectively differentiating pancreatic neuroendocrine tumors (PNETs) from pancreatic cancer.</p><p><strong>Methods: </strong>A total of 257 patients, including 151 with pancreatic cancer and 106 with PNETs, were retroactively enrolled after confirmation through pathological examination. These patients were randomized to either the training or test cohort in a ratio of 7:3. Radiomic features were extracted from the intratumoral and peritumoral regions from conventional EUS images. Following this, the radiomic features underwent dimensionality reduction through the utilization of the least absolute shrinkage and selection operator (LASSO) algorithm. Six machine learning algorithms were utilized to train prediction models employing features with nonzero coefficients. The optimum intratumoral radiomic model was identified and subsequently employed for further analysis. Furthermore, a combined radiomic model integrating both intratumoral and peritumoral radiomic features was established and assessed based on the same machine learning algorithm. Finally, a nomogram was constructed, integrating clinical signature and combined radiomics model.</p><p><strong>Results: </strong>107 radiomic features were extracted from EUS and only those with nonzero coefficients were kept. Among the six radiomic models, the support vector machine (SVM) model had the highest performance with AUCs of 0.853 in the training cohort and 0.755 in the test cohort. A peritumoral radiomic model was developed and assessed, achieving an AUC of 0.841 in the training and 0.785 in the test cohorts. The amalgamated model, incorporating intratumoral and peritumoral radiomic features, exhibited superior predictive accuracy in both the training (AUC=0.861) and test (AUC=0.822) cohorts. These findings were validated using the Delong test. The calibration and decision curve analyses (DCA) of the combined radiomic model displayed exceptional accuracy and provided the greatest net benefit for clinical decision-making when compared to other models. Finally, the nomogram also achieved an excellent performance.</p><p><strong>Conclusions: </strong>An efficient and accurate EUS-based radiomic model incorporating intratumoral and peritumoral radiomic features was proposed and validated to accurately distinguish PNETs from pancreatic cancer. This research has the potential to offer novel perspectives on enhancing the clinical utility of EUS in the prediction of PNETs.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1442209"},"PeriodicalIF":3.5,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11913666/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum: A simplified frailty index and nomogram to predict the postoperative complications and survival in older patients with upper urinary tract urothelial carcinoma.","authors":"Jianyong Liu, Haoran Wang, Pengjie Wu, Jiawen Wang, Jianye Wang, Huimin Hou, Jianlong Wang, Yaoguang Zhang","doi":"10.3389/fonc.2025.1575599","DOIUrl":"https://doi.org/10.3389/fonc.2025.1575599","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.3389/fonc.2023.1187677.].</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1575599"},"PeriodicalIF":3.5,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11916989/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A meta-analysis and systematic review of different cyclin-dependent kinase 4/6 inhibitors in breast cancer.","authors":"Jialin Zhang, Xinyu Xu, Yeyue Zhou, Jingyang Su, Jue Wang","doi":"10.3389/fonc.2025.1472407","DOIUrl":"10.3389/fonc.2025.1472407","url":null,"abstract":"<p><strong>Objective: </strong>The objective of this study was to assess the effectiveness and safety of CDK4/6 inhibitors in the treatment of hormone receptor-positive (HR+) breast cancer by using meta-analysis.</p><p><strong>Methods: </strong>To gather comprehensive and reliable data for our analysis, we systematically searched multiple databases for relevant studies. We utilized RevMan5.3 software to perform the meta-analysis.</p><p><strong>Results: </strong>Following a rigorous screening and evaluation process, we ultimately included a total of 13 studies in our analysis. Our findings showed that compared to endocrine therapy alone, the combination of CDK4/6 inhibitors with endocrine therapy significantly increased both PFS [HR 0.54 (95%CI: 0.50, 0.58), <i>P<0.00001</i>], OS [HR 0.77 (95%CI: 0.50, 0.58), <i>P<0.00001</i>] and ORR [RR 1.39 (95% CI: 1.21, 1.60), <i>P<0.00001</i>). However, it was also found that CDK4/6 inhibitors caused adverse drug reactions related to the blood system and digestive system (<i>P<0.0001</i>).</p><p><strong>Conclusions: </strong>Our meta-analysis demonstrates that the addition of CDK4/6 inhibitors to endocrine therapy can result in improved PFS and OS for HR+ breast cancer patients. Meanwhile, we recommend close monitoring and management of these potential side effects when utilizing these inhibitors in breast cancer treatment.</p><p><strong>Systematic review registration: </strong>https://www.crd.york.ac.uk/PROSPERO, identifier CRD42023490499.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1472407"},"PeriodicalIF":3.5,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11913826/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case Report: <i>BRCA1</i> and <i>BRCA2</i> loss in a young man with primary cutaneous extraskeletal osteosarcoma.","authors":"Wen-Feng Luo, Yu-Hang Hou, Yu-Teng Huang, Jun-Dong Lai, Hui-Shan Jiang, Wei-Liang Wang","doi":"10.3389/fonc.2025.1504366","DOIUrl":"10.3389/fonc.2025.1504366","url":null,"abstract":"<p><strong>Background: </strong>Extraskeletal osteosarcoma is an uncommon and high-grade soft tissue malignancy. The incidence is even lower when the skin is the primary site. To the best of our knowledge, the primary cutaneous osteosarcoma has fewer than 30 reported cases worldwide, which with decreased copy number of<i>BRCA1</i> and <i>BRCA2</i> has never been reported before.</p><p><strong>Case presentation: </strong>A 28-year-old man was hospitalized for a skin mass on the left shoulder. The histological examination showed a large number of tumor giant cells and fibroblasts, and nuclear division was easy to see. Immunohistochemistry showed positive for CK, EMA, S100, CD34, CK7, Bcl-2, ACTin, and NSE, and negative for Vim, SATB2, CD99, SMA (focal), and Ki67 was about 40%. Shoulder joint CT and PET-CT showed that no metastasis presented. Germline testing showed decreased copy number of<i>BRCA1</i> and <i>BRCA2</i>. The diagnosis was cutaneous extraskeletal osteosarcomas of the left shoulder. The patient underwent an enlarged resection, followed by local radiotherapy four cycles. No recurrence or metastasis occurred on a 1-year of follow-up.</p><p><strong>Conclusions: </strong>Primary cutaneous extraskeletal osteosarcoma (PC-EOS) is rare, and preoperative differential diagnosis is difficult. This is the first report of PC-EOS with decreased copy number of <i>BRCA1</i> and <i>BRCA2</i>. The presented case highlights the importance of accurate histopathological examination and comprehensive analysis. We considered that <i>BRCA1</i> and <i>BRCA2</i> genes may are associated with a worse outcome and local recurrence in PC-EOS. But, it may not have been fully recognized.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1504366"},"PeriodicalIF":3.5,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11914087/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emerging clinical and research approaches in targeted therapies for high-risk neuroblastoma.","authors":"Albatool AlKhazal, Samiha Chohan, Destani J Ross, Jinhwan Kim, Erin G Brown","doi":"10.3389/fonc.2025.1553511","DOIUrl":"10.3389/fonc.2025.1553511","url":null,"abstract":"<p><p>Neuroblastoma is a pediatric cancer that originates from neural crest cells and is the most common extracranial solid tumor in children under five years of age. While low-risk neuroblastoma often regresses spontaneously, high-risk neuroblastoma poses a significant clinical challenge. Recent advances in understanding neuroblastoma's molecular mechanisms have led to the development of targeted therapies that aim to selectively inhibit specific pathways involved in tumor growth and progression, improving patient outcomes while minimizing side effects. This review provides a comprehensive review of neuroblastoma biology and emerging therapeutic strategies. Key topics include (a) immunotherapies and immunotargets, (b) non-coding RNAs (long non-coding RNA, microRNA, and circular RNA), (c) molecular biomarkers and pathways, and (d) limitations and future directions.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1553511"},"PeriodicalIF":3.5,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11913827/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acetylated <i>Dendrobium huoshanense</i> polysaccharide: a novel inducer of apoptosis in colon cancer cells via Fas-FasL pathway activation and metabolic reprogramming.","authors":"Liang Yao, Chen Gu, Ruipeng Ge, Xiaoqian Zhang, Xinqian Meng, Lei Wang, Daiyin Peng, Guozhuan Li","doi":"10.3389/fonc.2025.1529868","DOIUrl":"10.3389/fonc.2025.1529868","url":null,"abstract":"<p><strong>Introduction: </strong>Not all polysaccharides function as antitumor drugs, nor do they universally possess the same advantages regarding safety and biocompatibility. Those polysaccharides that are effective antitumor agents typically demonstrate superior safety profiles and biocompatibility compared to synthetic anticancer drugs, which can exhibit high toxicity and harmful side effects. <i>Dendrobium huoshanense</i> polysaccharide (DHP) has been recognized for its potential bioactive properties, particularly in anti-tumor treatment. This study investigates the effects of DHP on the proliferation and apoptosis of HCT116 colon cancer cells.</p><p><strong>Methods: </strong>DHP was extracted according to previously published experimental methods. The inhibitory effects of DHP were evaluated using IEC6, Caco-2, and HCT116 cell lines, with changes in cell morphology observed via transmission electron microscopy. After establishing the conditions for DHP administration, flow cytometry was employed to assess its effects on apoptosis, reactive oxygen species (ROS), and mitochondrial membrane potential of HCT116 cells. Additionally, immunoprecipitation, quantitative real-time polymerase chain reaction (qRT-PCR), Western blotting, and biomarker detection were utilized to investigate the mechanisms underlying DHP's inhibition of HCT116 cells and its impact on metabolic reprogramming.</p><p><strong>Results: </strong>In the present study, we observed that DHP treatment at 600 μg/ml for 24 h reduced HCT116 cell viability to 54.87%. In contrast, the inhibitory effect of DHP on the viability of IEC6 and Caco-2 cells was relatively mild. The specific mechanism involves DHP activating the mitochondrial apoptotic pathway leading to the downregulation of key metabolic intermediates and enzymes such as uridine diphosphate N-acetylglucosamine (UDP-GlcNAc) and ST6Gal-I. By inhibiting ST6Gal-I activity, DHP activates the Fas/FasL signaling pathway. Additionally, DHP-induced ROS production effectively triggers apoptosis in HCT116 cells.</p><p><strong>Conclusion: </strong>Our study demonstrates that DHP effectively inhibits the proliferation and induces apoptosis in HCT116 colon cancer cells through the activation of the Fas-FasL signaling pathway and metabolic reprogramming. The selective inhibitory effect of DHP on HCT116 cells, the activation of both death receptor and mitochondrial apoptotic pathways, and the modulation of metabolic reprogramming provide novel insights into the potential therapeutic strategies for colon cancer.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1529868"},"PeriodicalIF":3.5,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11913854/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial: Diagnosis and treatment of vulvar cancer.","authors":"Violante Di Donato, Tullio Golia D'Augè, Giorgio Bogani, Andrea Giannini","doi":"10.3389/fonc.2025.1569255","DOIUrl":"10.3389/fonc.2025.1569255","url":null,"abstract":"","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1569255"},"PeriodicalIF":3.5,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11915101/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}